-
1 Comment
Genscript Biotech Corporation is currently in a long term uptrend where the price is trading 114.1% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.1.
Finally, its free cash flow fell by 196.6% to $-59M since the same quarter in the previous year.
Based on the above factors, Genscript Biotech Corporation gets an overall score of 2/5.
Industry | Biotechnology |
---|---|
Exchange | F |
CurrencyCode | EUR |
Sector | Healthcare |
ISIN | KYG3825B1059 |
Beta | 0.97 |
---|---|
Market Cap | 3B |
PE Ratio | None |
Target Price | None |
Dividend Yield | None |
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products. The Life Science Services and Products segment provides products and services in various categories, including gene synthesis, oligonucleotide synthesis, peptide synthesis, protein engineering, antibody development, and life-science equipment and consumables, such as molecular diagnostics tools and genome editing materials for biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and the food industry. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for G51.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025